---
type: source
title: "WeightWatchers Med+ GLP-1 Success Program: 61% More Weight Loss Month 1, 21% at 12 Months with Behavioral Integration (March 2026)"
author: "WeightWatchers (internal analysis, March 2026)"
url: https://www.weightwatchers.com
date: 2026-03-01
domain: health
secondary_domains: []
format: report
status: processed
processed_by: vida
processed_date: 2026-04-13
priority: medium
tags: [glp1, behavioral-wraparound, adherence, weight-loss, digital-health, ww-med-plus]
extraction_model: "anthropic/claude-sonnet-4.5"
---

## Content

WeightWatchers Med+ GLP-1 Success Program internal analysis (March 2026, n=3,260 Med+ members prescribed GLP-1):

**Weight loss outcomes (medication + behavioral program vs. medication alone):**
- Month 1: 61.3% more body weight loss with behavioral program vs. medication alone
- 12-month average: 21.0% body weight loss
- 24-month average: 20.5% — sustained without significant regain

**Behavioral program components:**
- GLP-1 prescriptions via WW telehealth
- Behavioral platform: nutrition coaching, community, dietitian access, workshops, app tracking
- Side effect support: 72% of program members reported GLP-1 Success Program helped minimize side effects

**Persistence comparison:** Not explicitly reported in this analysis (see Omada and Noom for persistence data).

**Key finding for continuous-delivery debate:**
- 24-month average (20.5%) shows sustained weight loss, not plateau or regain
- Duration of data coverage (2 years) partially addresses the continuous-delivery question — though all members are presumably still on GLP-1 at 24 months (no post-discontinuation data from WW)

**Methodological caveats:**
- Internal analysis by WeightWatchers — financial incentive to show positive outcomes
- No sample size, control group details, or statistical methodology disclosed in press release
- "Medication alone" comparator group: unclear if this is historical data, concurrent comparison, or matched controls — this matters significantly for interpreting the 61.3% month-1 advantage

## Agent Notes
**Why this matters:** The 61% more weight loss in month 1 with behavioral integration is a large effect size and the 24-month sustained data (20.5% without regain) is important for the continuous-delivery vs. durable effect debate. However, WW's data is the least methodologically transparent of the major programs — no sample size or statistical methods disclosed.

**What surprised me:** The 24-month figure (20.5%) being nearly identical to the 12-month figure (21.0%). This suggests plateau, not continued loss — but importantly, no regain either. Plateau with GLP-1 + behavior is better than the typical cessation pattern (significant regain).

**What I expected but didn't find:** Post-discontinuation data. WW Med+ doesn't report what happens when members stop GLP-1s — they only report outcomes for current program members. The Omada post-discontinuation data remains the only finding on this.

**KB connections:**
- GLP-1 behavioral adherence thread (this session)
- Omada post-discontinuation data (comparable program type, different finding emphasis)
- Continuous-delivery requirement debate

**Extraction hints:**
- Not a strong standalone extraction target due to methodological opacity
- Better used as one data point in a broader "behavioral wraparound improves GLP-1 outcomes" claim alongside Omada, Calibrate, Noom data
- The "72% found program helped minimize side effects" is potentially extractable as a behavioral factor in adherence

**Context:** WeightWatchers rebranded to WW and launched a telehealth/GLP-1 platform (Med+) to compete with Noom, Calibrate, Omada, Ro. They have significant brand recognition and an existing community platform but are newer to the GLP-1 space than some competitors.

## Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: Behavioral wraparound for GLP-1 adherence thread
WHY ARCHIVED: 24-month sustained weight loss data (20.5%) adds to the body of evidence that behavioral programs can extend GLP-1 benefit duration; complements Omada post-discontinuation finding
EXTRACTION HINT: Use as supporting evidence for a compound claim about behavioral wraparound + GLP-1 outcomes, not as a standalone primary source. Flag methodological opacity.
